Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.48 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829512 | 0.89 | MCL1 (0.43) | MRGPRX4HPGDRXRARXRBALDH1A1 | |
| SCHEMBL14829856 | 0.89 | MRGPRX4 (0.46) | MRGPRX4HPGDRXRARXRBALDH1A1 | |
| SCHEMBL14829711 | 0.89 | PTGER1 (0.45) | MRGPRX4HPGDRXRARXRBALDH1A1 | |
| SCHEMBL14829599 | 0.88 | MRGPRX4 (0.47) | MRGPRX4DOT1L | |
| SCHEMBL14829661 | 0.84 | MRGPRX4 (0.46) | MRGPRX4CLCN2CHRM4CHRM3HPGD | |
| SCHEMBL14829678 | 0.81 | MRGPRX4 (0.48) | MRGPRX4RXRARXRBNPC1RAB9A | |
| SCHEMBL14829578 | 0.81 | PTGER1 (0.47) | MRGPRX4HPGDALDH1A1MAPTNPC1 | |
| SCHEMBL14829632 | 0.80 | MAOB (0.46) | MRGPRX4NPC1RAB9A | |
| SCHEMBL14829747 | 0.80 | SRD5A2 (0.47) | MRGPRX4ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL14829843 | 0.80 | MRGPRX4 (0.48) | MRGPRX4HPGDRXRARXRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | claimed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | claimed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | disclosed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, RAF1 | MRGPRX4 2329/4885CLCN2 3490/4885CHRM4 4318/4885 |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MRGPRX4 2298/4885CLCN2 3740/4885CHRM4 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.